Overview
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.
Description
This is an observational cohort study that will enroll patients with DTC metastatic to the lungs who will receive oncogene-specific targeted therapy as part of routine clinical care or a separate therapeutic clinical trial. After approximately 4 weeks of therapy, patients will have a whole body scan to determine the change in RAI-avidity of their tumor from baseline. Subsequent therapy will be at the discretion of the treating physician or according to the therapeutic trial on which the patient is enrolled.
Eligibility
Inclusion Criteria (Prospective Cohort):
- Patients with a histologic diagnosis of differentiated thyroid cancer
- Presence of an neurotrophic tyrosine kinase receptors (NTRK)-fusion, RET-fusion, anaplastic lymphoma kinase (ALK)-fusion, BRAF V600 mutation, BRAF-fusion or other targetable alteration identified in a Clinical Laboratory Improvement Amendments/College of American Pathologists (CLIA/CAP) laboratory
- Anatomically evaluable disease on chest Computed tomography (CT) meeting oneo f the
following criteria (obtained within 180 days of enrollment):
- multiple (10 or more) noncalcified solid pulmonary nodules visible on CT and/or
- enlarging, discrete pulmonary nodules visible on CT of any number consistent with metastatic disease
- Patients for whom systemic therapy with an oncogene-specific kinase inhibitor is
planned from commercial supply or as part of a separate therapeutic clinical trial (that does not include data sharing with this protocol)/compassionate access protocol/single patient investigational new drug (IND). Such agents include, but are not limited to:
- Larotrectinib, entrectinib, selitrectinib, and repotrectinib for NTRK fusions
- Selpercatinib and pralsetinib for RET fusions
- Crizotinib, lorlatinib, repotrectinib, and alectinib for ALK fusions
- Dabrafenib and/or trametinib for BRAF V600 mutations
- Oncogene-specific kinase inhibitors other than those specifically delineated above must be approved by the overall study PI prior to enrollment
Inclusion Criteria (Data Sharing Cohort):
- Patients enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing as part of the consent process for that trial.
Exclusion Criteria (All Cohorts):
- No prior oncogene-specific targeted therapy allowed. However, patients may enroll within 4 weeks of starting oncogene-specific therapy if a pre-therapy WBS is available. Prior therapy with non-oncogene specific multi-thyrosine kinase inhibitors (such as sorafenib, lenvatinib, and/or cabozantanib) is allowed.
- Females who are pregnant or breastfeeding are excluded due to the potential risks of the RAI used in the WBS to the fetus/neonate.
- Patients who require sedation/general anesthesia to complete a WBS are excluded.
- U.S. Military Personnel are excluded due to the Children's Hospital of Philadelphia (CHOP) Institutional Review Board (IRB) requirements.